Bristol-Myers Squibb (BMY) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
24.3B, trading at $60.87 on the NYSE. This SniperIQ fundamentals page covers Bristol-Myers Squibb's valuation (P/E 17.1x, P/B 6.2x), profitability (net margin 15.0%), revenue ($48.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
24.3B
P/E (TTM)17.1x
Net Margin15.0%
Revenue (FY25)$48.2B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Bristol-Myers Squibb's market cap?
Bristol-Myers Squibb (BMY) has a market capitalization of approximately
24.3B, trading at $60.87 on the NYSE. Market cap moves with the live share price.
What is Bristol-Myers Squibb's P/E ratio?
Bristol-Myers Squibb's trailing twelve-month P/E ratio is 17.1x, with a price-to-book (P/B) of 6.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bristol-Myers Squibb?
Bristol-Myers Squibb runs a net profit margin of 15.0%, a gross margin of 68.7%, and an operating margin of 25.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bristol-Myers Squibb generate?
Bristol-Myers Squibb reported revenue of $48.2B for fiscal year 2025, with net income of $7.1B and earnings per share (EPS) of 3.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bristol-Myers Squibb pay a dividend?
Bristol-Myers Squibb offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bristol-Myers Squibb financially healthy?
Bristol-Myers Squibb carries a debt-to-equity ratio of 2.22x and a current ratio of 1.42x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bristol-Myers Squibb a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bristol-Myers Squibb (BMY) the key facts are: market cap
24.3B, P/E 17.1x, revenue $48.2B, 52-week range 42.52-62.89. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bristol-Myers Squibb's full fundamentals live
Get Bristol-Myers Squibb's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.